Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCK1 | P35558 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980864 | 0.92 | PCK1 (0.81) | PCK1 | |
| SCHEMBL4614581 | 0.91 | PCK1 (0.72) | PCK1 | |
| SCHEMBL3978767 | 0.90 | PCK1 (1.00) | PCK1 | |
| SCHEMBL3983096 | 0.90 | PCK1 (0.87) | PCK1 | |
| SCHEMBL3983384 | 0.89 | PCK1 (0.88) | PCK1 | |
| SCHEMBL3981765 | 0.87 | PCK1 (0.95) | PCK1 | |
| Trifluoroacetic Acid SCHEMBL4614421 | 0.87 | PCK1 (0.88) | PCK1 | |
| SCHEMBL3977016 | 0.86 | PCK1 (0.83) | PCK1 | |
| SCHEMBL6443781 | 0.86 | PCK1 (0.81) | PCK1 | |
| SCHEMBL3978659 | 0.86 | PCK1 (1.00) | PCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515972-B1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-05-13 | — | — | EP | claimed |
| EP-1599477-B1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-30 | — | — | EP | claimed |
| US-7148229-B2 | Sulfonamide substituted xanthine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-12-12 | — | — | US | claimed |
| US-7135475-B2 | Antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2006-11-14 | — | — | US | claimed |
| EP-1599477-A1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-30 | — | — | EP | claimed |
| EP-1515972-A1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-23 | — | — | EP | claimed |
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | DUNTEN PETER W (US) | 2004-09-30 | — | — | US | claimed |
| WO-2004074288-A1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-02 | — | — | WO | claimed |
| US-20040014766-A1 | Amide substituted xanthine derivatives | HOFFMANN-LA ROCHE INC. | 2004-01-22 | — | — | US | claimed |
| WO-2003106459-A1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-24 | — | — | WO | claimed |
| EP-1515972-B1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-05-13 | — | — | EP | disclosed |
| EP-1599477-B1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-30 | — | — | EP | disclosed |
| US-7148229-B2 | Sulfonamide substituted xanthine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7135475-B2 | Antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1599477-A1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-30 | — | — | EP | disclosed |
| EP-1515972-A1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | DUNTEN PETER W (US) | 2004-09-30 | — | — | US | disclosed |
| WO-2004074288-A1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-02 | — | — | WO | disclosed |
| US-20040014766-A1 | Amide substituted xanthine derivatives | HOFFMANN-LA ROCHE INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003106459-A1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014766-A1 | Amide substituted xanthine derivatives | GYS2, GLS2, PYGL | PCK1 14/4885 |
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | GYS2, SLC5A1, SLC5A2 | PCK1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.